This clinical trial, sponsored by Banner Health, investigates the efficacy and safety of donanemab and RG6289 in treating Autosomal-Dominant Alzheimer's Disease (ADAD) in PSEN1 E280A mutation carriers. The trial's dual approach—targeting both amyloid and tau—positions it strategically in the competitive landscape of Alzheimer's therapeutics, where combination therapies are gaining traction. The estimated enrollment of 240 participants and the involvement of notable collaborators, including the National Institute on Aging, enhance the study's credibility. The trial's outcomes could significantly influence market dynamics, particularly if positive results are achieved, potentially leading to a first-in-class combination therapy for ADAD.